Target Price | $509.69 |
Price | $493.84 |
Potential | 3.21% |
Number of Estimates | 26 |
26 Analysts have issued a price target Vertex Pharmaceuticals 2026 . The average Vertex Pharmaceuticals target price is $509.69. This is 3.21% higher than the current stock price. The highest price target is $617.00 24.94% , the lowest is $330.00 33.18% . | |
A rating was issued by 35 analysts: 20 Analysts recommend Vertex Pharmaceuticals to buy, 13 to hold and 2 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Vertex Pharmaceuticals stock has an average upside potential 2026 of 3.21% . Most analysts recommend the Vertex Pharmaceuticals stock at Purchase. |
28 Analysts have issued a sales forecast Vertex Pharmaceuticals 2025 . The average Vertex Pharmaceuticals sales estimate is $12.0b . This is 9.14% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $12.4b 13.31% , the lowest is $11.8b 6.98% .
This results in the following potential growth metrics:
2024 | $11.0b | 11.64% |
---|---|---|
2025 | $12.0b | 9.14% |
2026 | $13.2b | 9.97% |
2027 | $14.4b | 9.16% |
2028 | $15.6b | 8.34% |
2029 | $17.3b | 11.08% |
8 Analysts have issued an Vertex Pharmaceuticals EBITDA forecast 2025. The average Vertex Pharmaceuticals EBITDA estimate is $5.6b . This is 23,035.69% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $6.1b 25,161.61% , the lowest is $4.9b 19,941.36% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | $4.6b | 2.39% |
---|---|---|
2025 | $5.6b | 22.64% |
2026 | $6.8b | 22.00% |
2027 | $7.6b | 10.77% |
2028 | $8.2b | 8.70% |
2029 | $9.1b | 10.19% |
2024 | 41.56% | 8.29% |
---|---|---|
2025 | 46.70% | 12.37% |
2026 | 51.81% | 10.94% |
2027 | 52.57% | 1.47% |
2028 | 52.75% | 0.34% |
2029 | 52.32% | 0.82% |
20 Vertex Pharmaceuticals Analysts have issued a net profit forecast 2025. The average Vertex Pharmaceuticals net profit estimate is $4.2b . This is 836.08% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $4.7b 927.27% , the lowest is $3.6b 734.55% .
This results in the following potential growth metrics and future Net Margins:
2024 | $-534m | 114.97% |
---|---|---|
2025 | $4.2b | 878.55% |
2026 | $4.8b | 15.41% |
2027 | $5.3b | 9.87% |
2028 | $6.3b | 18.78% |
2029 | $6.8b | 8.84% |
2024 | -4.87% | 113.41% |
---|---|---|
2025 | 34.71% | 813.40% |
2026 | 36.42% | 4.93% |
2027 | 36.66% | 0.66% |
2028 | 40.20% | 9.66% |
2029 | 39.39% | 2.01% |
20 Analysts have issued a Vertex Pharmaceuticals forecast for earnings per share. The average Vertex Pharmaceuticals EPS is $16.19 . This is 835.91% higher than earnings per share in the financial year 2024. The highest EPS forecast is $18.20 927.27% , the lowest is $13.96 734.55% .
This results in the following potential growth metrics and future valuations:
2024 | $-2.08 | 114.97% |
---|---|---|
2025 | $16.19 | 878.37% |
2026 | $18.69 | 15.44% |
2027 | $20.53 | 9.84% |
2028 | $24.39 | 18.80% |
2029 | $26.55 | 8.86% |
Current | -224.30 | 890.35% |
---|---|---|
2025 | 30.50 | 113.60% |
2026 | 26.42 | 13.38% |
2027 | 24.05 | 8.97% |
2028 | 20.25 | 15.80% |
2029 | 18.60 | 8.15% |
Based on analysts' sales estimates for 2025, the Vertex Pharmaceuticals stock is valued at an EV/Sales of 10.23 and an P/S ratio of 10.59 .
This results in the following potential growth metrics and future valuations:
Current | 11.16 | 20.13% |
---|---|---|
2025 | 10.23 | 8.38% |
2026 | 9.30 | 9.07% |
2027 | 8.52 | 8.39% |
2028 | 7.86 | 7.70% |
2029 | 7.08 | 9.98% |
Current | 11.56 | 11.66% |
---|---|---|
2025 | 10.59 | 8.38% |
2026 | 9.63 | 9.07% |
2027 | 8.82 | 8.39% |
2028 | 8.14 | 7.70% |
2029 | 7.33 | 9.98% |
Vertex Pharmaceuticals...
Analyst | Rating | Action | Date |
---|---|---|---|
RBC Capital |
Sector Perform
➜
Sector Perform
|
Unchanged | Apr 01 2025 |
B of A Securities |
Buy
➜
Buy
|
Unchanged | Mar 31 2025 |
RBC Capital |
Sector Perform
➜
Sector Perform
|
Unchanged | Feb 20 2025 |
Canaccord Genuity |
Sell
➜
Hold
|
Upgrade | Feb 12 2025 |
Barclays |
Equal-Weight
➜
Equal-Weight
|
Unchanged | Feb 11 2025 |
HC Wainwright & Co. |
Buy
➜
Buy
|
Unchanged | Feb 11 2025 |
Needham |
Hold
➜
Hold
|
Unchanged | Feb 11 2025 |
Analyst Rating | Date |
---|---|
Unchanged
RBC Capital:
Sector Perform
➜
Sector Perform
|
Apr 01 2025 |
Unchanged
B of A Securities:
Buy
➜
Buy
|
Mar 31 2025 |
Unchanged
RBC Capital:
Sector Perform
➜
Sector Perform
|
Feb 20 2025 |
Upgrade
Canaccord Genuity:
Sell
➜
Hold
|
Feb 12 2025 |
Unchanged
Barclays:
Equal-Weight
➜
Equal-Weight
|
Feb 11 2025 |
Unchanged
HC Wainwright & Co.:
Buy
➜
Buy
|
Feb 11 2025 |
Unchanged
Needham:
Hold
➜
Hold
|
Feb 11 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.